BioSante Pharmaceuticals to Present at Wall Street Reporter Small-Cap Discovery Conference
13 September 2005 - 11:00PM
Business Wire
BioSante Pharmaceuticals (AMEX:BPA) today announced that Stephen M.
Simes, president and chief executive officer, will present a
corporate overview at Wall Street Reporter magazine's sixth annual
Small-Cap Discovery Conference. The presentation will take place on
Thursday, September 15 at 10:50 a.m. EDT at The Lotos Club in New
York City. BioSante is one of six companies selected to participate
in the half-day event designed to provide fund managers and
analysts with insight into new trends and investment opportunities
in the small-cap marketplace. To attend the Small-Cap Discovery
Conference, visit http://www.wallstreetreporter.com/sdc2/ for
registration and additional information. Also, a live webcast of
the entire conference will be available online beginning at 8:00
a.m. EDT on September 13. The webcast can be accessed at
http://www.investorcalendar.com/VC/index.asp by clicking on the
Wall Street Reporter icon. About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver
bioidentical estradiol and testosterone. BioSante's lead products
include Bio-E-Gel(TM) (bioidentical estradiol gel) for the
treatment of women with menopausal symptoms, and LibiGel(TM)
(bioidentical testosterone gel) for the treatment of female sexual
dysfunction (FSD). The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion. The
transdermal gel formulations used in the women's gel products are
licensed by BioSante from Antares Pharma Inc. (Amex:AIS). The
company also is developing its calcium phosphate nanotechnology
(CaP) for novel vaccines, including biodefense vaccines for toxins
such as anthrax and ricin, and drug delivery systems. Additional
information is available online at: www.biosantepharma.com. This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. The
statements regarding BioSante contained in this press release that
are not historical in nature, particularly those that utilize
terminology such as "may," "will," "should," "likely," "expects,"
"anticipates," "estimates," "believes" or "plans," or comparable
terminology, are forward-looking statements. Forward-looking
statements are based on current expectations and assumptions, and
entail various risks and uncertainties that could cause actual
results to differ materially from those expressed in such
forward-looking statements. Important factors known to BioSante
that cause actual results to differ materially from those expressed
in such forward-looking statements are the difficulty of developing
pharmaceutical products, obtaining regulatory and other approvals
and achieving market acceptance, and other factors identified and
discussed from time to time in BioSante's filings with the
Securities and Exchange Commission, including those factors
discussed on pages 19 to 31 of BioSante's Form 10-KSB, which
discussion also is incorporated herein by reference. All
forward-looking statements speak only as of the date of this news
release. BioSante undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Biosante Pharmaceuticals (American Stock Exchange): 0 recent articles
More BioSante Pharmaceuticals, Inc. News Articles